Adenosine acts as an inhibitor of lymphoma cell growtha major role for the A3 adenosine receptor

European Journal of Cancer

Volumn 36, Issue 11, 2000, Pages 1452-1458

  Fishman, P ^a   Bar Yehuda, S ^a   Ohana, G ^a   Pathak, S ^b   Wasserman, L ^a   Barer, F ^a   Multani, A S ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adenosine; Adenosine receptors; Cell cycle; Lymphoma cells; Telomeric DNA

Indexed keywords

2 CHLORO 6 N CYCLOPENTYLADENOSINE; 3,7 DIMETHYL 1 PROPARGYLXANTHINE; 6 N [2 (3,5 DIMETHOXYPHENYL) 2 (2 METHYLPHENYL)ETHYL]ADENOSINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURYL) 5 PHENYLACETYLAMINO 1,2,4 TRIAZOLO[1,5 C]QUINAZOLINE; ADENOSINE; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPHOMA CELL; PRIORITY JOURNAL; TELOMERE;

ADENOSINE; ANIMALS; APOPTOSIS; CELL DIVISION; DNA, NEOPLASM; LYMPHOMA; RATS; RECEPTOR, ADENOSINE A3; RECEPTORS, PURINERGIC P1; TELOMERE; TUMOR CELLS, CULTURED;

EID: 0033921004     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00130-1     Document Type: Article

References (39)

1. Linden J. Structure and function of A1 adenosine receptors. FASEB J. 5:1991;2668-2676.
2. Stiles G.L. Adenosine receptors and beyond. molecular mechanisms of physiological regulation Clin. Res. 38:1990;10-18.
3. Clarke B., Coupe M. Adenosine. cellular mechanisms, patho-physiological roles and clinical applications Int. J. Cardiol. 23:1989;1-10.
4. Poulsen S.A., Quinn R.J. Adenosine receptors. new opportunities for future drugs Bioorg. Med. Chem. 6:1998;619-641.
5. MacLaughlin M., Martinez-Salgado C., Eleno N., Olivera A., Lopez-Novoa J.M. Adenosine activates mesangial cell proliferation. Cell Signal. 9:1997;59-63.
6. Shimegi S. Mitogenic action of adenosine on osteoblast-like cells, MC3T3-E1. Calcif. Tissue Int. 62:1998;418-425.
7. Sandberg G. Regulation of thymocyte proliferation by endogenous adenosine and adenosine deaminase. Int. J. Immunopharmacol. 5:1983;259-265.
8. Tey HB, Khoo HE, Tan CH. Adenosine modulates cell growth in human epidermoid carcinoma (A431) cells. Biochem Biophys Res Commun 1992, 30, 187(3), 1486-1492.
9. Colquhoun A., Newsholme E.A. Inhibition of human tumour cell proliferation by analogues of adenosine. Cell Biochem. Funct. 15:1997;135-139.
10. Bajaj S., Insel J., Quagliata F., Hirschhorn R., Silber R. Adenosine and adenosine analogues are more toxic to chronic lymphocytic leukemia than to normal lymphocytes. Blood. 62:1983;75-80.
11. Phillis J.W., O'Regan M.H. Prevention of ischemic brain injury by adenosine receptor activation. Drug Dev. Res. 28:1993;390-394.
12. Lasely R.D., Mentzer R.M. Myocardial protection. the adenosine theory Drug Dev. Res. 39:1996;314-318.
13. Von Lubitz D.K.J.E., Carter M.F., Beenhakker M., Lin R.C.S., Jacobson K.A. Adenosine. a prototherapeutic concept in neurodegeneration Ann. N. Y. Acad. Sci. 4:1995;163-178.
14. Collis M.G. The vasodilator role of adenosine. Pharmacol. Ther. 41:1989;143-162.
15. Soderback U., Sollevi A., Vallen V.H., Larsson P.T., Hjemdahl P. Anti-aggregatory effects of physiological concentrations of adenosine in human whole blood as assessed by filtragometry. Clin. Sci. 81:1991;691-694.
16. Paul P., Rothmann S.A., Meagher R.C. Modulation of erythropoietin production by adenosine. J. Lab. Clin. Med. 112:1988;168-173.
17. Elgler A., Greten T.F., Sinha B., Haslberger C., Sullivan G.W., Endres S. Endogenous adenosine curtails lipopolysaccharide-stimulated tumor necrosis factor synthesis. Scand. J. Immunol. 45:1997;132-139.
18. Gilbertsen R.B. Adenosine and adenosine receptors in immune function. Minireview and meeting report. Agents Actions. 22:1987;91-98.
19. Djaldetti M., Sredni B., Zigelma R., Verber M., Fishman P. Muscle cells secrete a low molecular weight factor with anti-cancerous activity. Clin. Exp. Metast. 14:1996;189-196.
20. Fishman P., Bar-Yehuda S., Wagman L. Adenosine and other low molecular weight factors released by muscle cells inhibit tumor cell growth. possible explanation for the rarity of metastases in muscle Cancer Res. 58:1998;3181-3187.
21. Pines M., Ashkenazi A., Cohen-Chapnik L., Binder L., Gertler A. Inhibition of the proliferation of Nb2 cells by femtomolar concentrations of cholera toxin and partial reversal of the effect by 12-0-tetradecanoyl-phorbol-13-acetate. J. Cell. Biochem. 37:1988;119-129.
22. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J. Cell. Biol. 66:1975;188-193.
23. Hare I.D., Bahler D.W. Analysis of Plasmodium falciparum growth in culture using acridine orange and flow cytometry. J. Histochem. Cytochem. 34:1986;215-220.
24. Pathak S. Chromosome banding techniques. J. Reprod. Med. 17:1976;25-28.
25. Multani A.S., Hopwood V.L., Pathak S. A modified fluorescence in situ hybridization (FISH) technique. Anticancer Res. 16:1996;3435-3437.
26. Kurland J.I., Hadden J.W., Moore M.A.S. Role of cyclic nucleotides in the proliferation of committed granulocyte-macrophage progenitor cells. Cancer Res. 37:1977;4534-4538.
27. kip1in G-CSF-treated NFS-60 cells. Biochem. Biophys. Res. Commun. 224:1996;10-16.
28. Skalhegg B.S., Johansen A.K., Levy F.O.et al. Isozymes of cyclic AMP-dependent protein kinases (PKA) in human lymphoid cell lines. levels of endogenous cAMP influence levels of PKA subunits and growth in lymphoid cell lines J. Cell. Physiol. 177:1998;85-93.
29. Rayhel E.J., Hughes J.P., Svihla D.A., Prentice D.A. Growth and protein phosphorylation in the Nb2 lymphoma. effect of prolactin, cAMP, and agents that activate adenylate cyclase J. Cell. Biochem. 43:1990;327-337.
30. Multani A.S., Ozen M., Sen S.et al. Amplification of telomeric DNA directly correlates with metastatic potential of human and murine cancers of various histological origin. Int. J. Oncol. 15:1999;423-429.
31. Kallassy M., Martel N., Damour O., Yamasaki H., Nakazawa H. Growth arrest of immortalized human keratinocytes and suppression of telomerase activity by p21WAF1 gene expression. Mol. Carcinogen. 21:1998;26-36.
32. Dawicki DD, Chatterjee D, Wyche J, Rounds S, et al. Extracellular ATP and adenosine cause apoptosis of pulmonary artery endothelial cells. Am J Physiol 1997, 273, 2Pt 1, L485-494.
33. Lewis M.D., Hepburn P.J., Scanlon M.F. Epidermal growth factor protects GH3 cells from adenosine induced growth arrest. Mol. Cell. Endocrinol. 2:1997;137-142.
34. Tanaka Y., Yoshihara K., Tsuyuki M., Tomoya K. Apoptosis induced by adenosine in human leukemia HL-60 cells. Exp. Cell. Res. 213:1994;242-252.
35. Seetulsingh-Goorah SP, Stewart BW. Growth inhibition of HL-60 cells by extracellular ATP: concentration - dependent involvement of a P2 receptor and adenosine generation. Biochem Biophys Res Commun 1998, 18, 250, 390-396.
36. Yao Y., Sei Y., Abbracchio M.P., Jiang J.L., Kim Y.C., Jacobson K.A. Adenosine A3 receptor agonists protect HL-60 and U-937 cells from apoptosis induced by A3 antagonists. Biochem. Biophys. Res. Commun. 232:1997;317-322.
37. Von Lubitz DK, Lin RC, Boyd MN, Bischofberger K, Jacobson A. Chronic administration of adenosine A3 receptor agonist and cerebral ischemia: neuronal and glial effects. Eur Pharmacol 1999, 19, 367, 157-163.
38. Stambaugh K., Jacobson K.A., Jiangand J.L., Liang B.T. A novel cardioprotective function of adenosine A1 and A3 receptors during prolonged simulated ischemia. Am. J. Physiol. 273:1997;H501-505.
39. Bowlin TL, Brocherding DR, Edwards 3rd CK, McWhinney CD. Adenosine A3 receptor agonists inhibit murine macrophage tumor necrosis factor-alpha production in vitro and in vivo. Cell Mol Biol 1997, 43, 345-349.